Cost–Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cost–Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France
Dermatol Ther (Heidelb) 2020 Sep 13;[EPub Ahead of Print], B Bregman, S Teitsson, I Orsini, FE Cotté, A Amadi, A Moshyk, S Roze, AF GaudinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.